Investigational PFO Closure Device
DeviceOcclutech Flex II PFO Closure Device
NCT Number: NCT05069558
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
University of Alberta Mazankowski Heart Institute, Edmonton, Alberta, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects with a PFO and cryptogenic stroke:
Exclusion criteria
Occlutech Flex II PFO Closure Device
Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Time frame: Twelve Months
Time frame: Enrollment to 12 Months
Time frame: Enrollment to Twelve Months, Annually thereafter.
Occlutech International AB
Industry
Prospective Randomized Multi-center Controlled Clinical Investigation Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
Acronym: OCCLUFLEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03309332
Brain Diseases, Cardiovascular Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT07380490
Brain Diseases, Brain Ischemia
View Trial DetailsNCT04950192
Aortic Valve Disease, Arrhythmias, Cardiac
Aurora, Colorado, United States
View Trial DetailsNCT05529901
Brain Diseases, Cardiovascular Abnormalities
Okayama, Japan
View Trial Details